Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thank you for the level headed response and honest opinion. We may not agree but the civility is appreciated.
I'm not really even sure what your point is in that reply. I was simply addressing your statement that number of shares doesn't matter, only market cap matters. When the market cap is continually increasing (thru issuance of more shares) and the value of my investment is continually decreasing, I would say that statement is categorically FALSE.
if you are speaking to me, I didn't say Authorized shares, I said outstanding shares which have been increased precipitously over the past 5 years. So it is you who either doesn't take the time to comprehend and read posts or it is you who doesn't understand.
It would also help people follow the chain if you reply to posts directly.
the patent lists 20+ different metals, one of which is Liquidmetal, that would be suitable for the invention. So while it's good to see Liquidmetal mentioned as a possible solution, I don't see how this patent translates categorically that a device made of Liquidmetal is imminent.
Is there more to it?
damn, someone pulled out the rug
damn...that bid support got demolished
termination of agreement (terms) Just a little light reading.
7.1. Term. The term of this Agreement commences on the Effective Date and shall continue in perpetuity unless the Parties mutually agree to terminate the Agreement or unless terminated earlier as set forth below.
7.2. Termination by Eontec. Eontec may terminate this Agreement upon written notice to LMT upon any of the following events:
(a) In the event LMT fails to increase the authorized shares of common stock to 1,100,000,000 by May 31, 2016; or
(b) LMT commits a material breach of this Agreement, the Purchase Agreement, or any other agreement to which Eontec (or its Affiliates) and LMT (or its Affiliates) are a party and fails to cure said breach within fifteen (15) Business Days of delivery of written notice of breach by Eontec to LMT.
7.3. Termination by LMT. LMT may terminate this Agreement upon written notice to Eontec upon any of the following events:
(a) Liquidmetal Technology Limited, a Hong Kong corporation, (or any permitted successor or assign) fails to purchase the Second Closing Shares and Third Closing Shares (as those terms are defined in the Purchase Agreement) when required to do so under the terms of the Purchase Agreement; or
(b) Eontec commits a material breach of this Agreement, the Purchase Agreement, or any other agreement to which Eontec (or its Affiliates) and LMT (or its Affiliates) are a party and fails to cure said breach within fifteen (15) Business Days of delivery of written notice of breach by LMT to Eontec; or
(c) Liquidmetal Technology Limited (or any permitted successor or assign) exercises the Put Right (as defined in the Purchase Agreement).
7.4. Effect of Termination. Within fifteen (15) Business Days after termination or expiration of this Agreement, each party shall: (a) immediately cease all activities concerning, including all practice and use of, the Intellectual Property that is licensed hereunder; (b) either return to each other all documents and tangible materials (and any copies) containing, reflecting, incorporating or based on Licensor's Confidential Information; or (ii) permanently erase such Confidential Information from its computer systems; and (c) certify in writing to the other party that it has complied with the requirements of Section 6.4(b). The rights and obligations of the parties set forth in this Section 6.4 and in Article 1 (Definitions), Section 4.2 (Improvements and Derivatives), Article 7 (Confidentiality), and Articles 8 (Miscellaneous), and any right, obligation or required performance of the Parties in this Agreement which, by its express terms or nature and context is intended to survive termination or expiration of this Agreement, shall survive any such termination or expiration.
some different math in this article regarding % of holdings.
http://www.4-traders.com/DONGGUAN-EONTEC-CO-LTD-12684676/news/Dongguan-Eontec-Plans-to-Buy-18-of-Liquidmetal-Technologies-22009842/
03/14/2016 | 09:06am US/Eastern
SHANGHAI, March 14, SinoCast -- Dongguan Eontec announces that a liquid metal company held by Li Yangde, effective controller of the company, plans to take over 18% equities in the OTCBB-liste4d Liquidmetal Technologies and signed a cooperation agreement.
The liquid metal business will be the first majority shareholder of Liquidmetal Technologies, and Li will be a director of the target and will raise holdings to 46%.
Established in May 2003, Liquidmetal Technologies is a world's leading player focusing on R&D and commercialization of bulk amorphous metals and a significant partner of Apple in bulk amorphous metal and technologies.
© Sinocast, source Sinocast Beats
point is well taken. I guess I got more caught up in the finished product which was pretty damn cool. Cooler and more applicable than that stupid ass knife.
ask thinning out too which is just an important. good to see sellers drying up.
great bid support, $78,000, wow.
agreed. just nice to see a finished product that would actually have demand and lead to revenue.
that's impressive....what the hell have we been doing?
very resilient today, now a $36,205 bid....that's encouraging
oh well, somebody dumped on it
nice $25,000 bid support at .132, hopefully doesn't get wiped out by a flipper
Do you have Level 2? Can you post screenshot please.
nice, bye bye .12
that is a great question. maybe someone will ask on the CC.
if I understand correctly the March 10th outstanding share count should be listed at 582 million. The other 300 million could be issued at some point in the future which at this time we would have no dates. You could note that the AUTHORIZED share count is pending shareholder vote to increase from 700m to 1.1b.
second attempt coming, might have been shaking the tree a little bit
i am not understanding your post. Only 105 million shares have been issued thus far. The remaining 300 million will only be issued upon certain conditions being met and could possibly never be issued. Why are you showing all 405 million OUTSTANDING as of 3/10/16? Thanks for the additional insight.
let's see what happens here to resistance at 12 cents........
Summary of Recent News & Upcoming Events
BIOMEDevice Conference San Jose, CA
December 7-8, 2016
http://biomedevicesj.mddionline.com/products#Liquidmetal-Technologies-Inc-
Liquidmetal Technologies Raises up to $63 Million in Partnership with Global Manufacturing Firm EONTEC
-Expands Global Footprint and Product Offering-
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--March 14, 2016--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT) ("LQMT"), the world's leading developer of amorphous alloys, announced today that it closed on a financing transaction of up to $63.4 million (initial closing occurred on March 10, 2016 in the amount of $8.4 million through the sale of equity to a private investor, with a commitment for an additional investment in the amount of $55.0 million subject to an increase in authorized shares to be approved by shareholders) . The investment was made in conjunction with a cross-licensing agreement with DongGuan EONTEC Co., Ltd. ("EONTEC"), a publicly traded company on the Shenzhen Stock Exchange (300328.sz).
EONTEC is a global manufacturing company headquartered in Hong Kong with manufacturing plants in China. It specializes in new material development, such as bulk metallic glasses and medical grade magnesium for implants. The company possesses a full set of mass production capabilities for zirconium based amorphous alloys, including material refining, tooling, and machining, surface treatment, as well as equipment and machine building capabilities for making large parts out of bulk metallic glass.
The equity investment in LQMT was made by Professor Lugee Li, who is also the Chairman and majority stockholder of EONTEC. Professor Li serves as an Analyst for the Institute of Metal Research at the Chinese Academy of Sciences and teaches at several universities in China. As part of the transaction, Professor Li was elected as a Board member of LQMT.
"EONTEC's capabilities complement LQMT's focus on production of high-performance parts, allowing LQMT to address a broad range of market opportunities from automotive, medical, and industrial customers. This partnership positions LQMT well to support design and production globally at a vastly increased pace," said Professor Li.
"This investment and partnership recognizes the significant advancements in technological and commercial capabilities that Liquidmetal has forged over the last five years. Our brand and market positions in North America and Europe are without peer," said Thomas Steipp, President and CEO at LQMT. "This financing transaction and cross-licensing agreement provides us with the platform and resources necessary to establish a global market in Liquidmetal(R) alloy solutions and to fast-track the market development of our core offerings. With this partnership, we will extend our capabilities to significantly larger parts, as well as offering substantially lower price points for some consumer markets. EONTEC and Liquidmetal each bring significant capabilities to this partnership, and we believe that result will be a much larger market that develops much more quickly," continued Mr. Steipp
Liquidmetal Technologies and C.F. Martin & Co. (R) Enter into Development Program
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--February 01, 2016--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys and composites, has entered into a development agreement with C.F. Martin & Co. (R) (Martin Guitar) to design a guitar component to be made of Liquidmetal amorphous alloys and manufactured utilizing the Liquidmetal injection molding machine.
Under the terms of their agreement, Martin Guitar will provide its expertise in design and innovation for producing acoustic instruments that have been acknowledged to be amongst the finest in the world. In collaboration with the Liquidmetal engineering team, the companies aim to identify, design and manufacture guitar components which benefit from the unique material properties and manufacturing methods of Liquidmetal amorphous alloys.
Tom Steipp, CEO of LQMT, stated "Liquidmetal has been associated with leading, world-class companies in various markets including consumer electronics and watches. Martin Guitar has a century long history distinguished by its contributions to and innovations in stringed acoustical instruments. We are pleased to collaborate with the Martin Guitar team."
More Than 200 Guests Visit a Liquidmetal Forum at ENGEL's Customer Center in Stuttgart, Germany
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--January 28, 2016--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys and composites, participated in an ENGEL hosted Liquidmetal Forum at its customer center in Stuttgart, Germany on January 19th and 20th. The special event, showcasing Liquidmetal's technology and ENGEL's injection molding machine, attracted more than 100 attendees on both days of the event. Approximately 50% of the attendees were not current customers of ENGEL signifying the ability of ENGEL to attract potential new customers.
Each day started with presentations from ENGEL, Liquidmetal, and Materion describing the overall manufacturing technology, equipment, and materials. The presentations were followed by a lunch served to all attendees and an afternoon demonstration by ENGEL, where Liquidmetal parts were produced in a fully automated injection molding work cell. During the afternoon process demonstration, individual panel of expert sessions were held by ENGEL and Liquidmetal with customers who requested one-on-one time to review their specific applications of interest for the technology.
"This event was an extraordinary opportunity to introduce the technology to such an excellent list of attendees. ENGEL did a fabulous job attracting top notch customers and went through an enormous amount of work to host the event in its beautiful Customer Center in Stuttgart," said Paul Hauck, Vice President of World-Wide Sales and Marketing. "The outstanding ENGEL event confirmed we made a good choice establishing manufacturing capacity in our Rancho Santa Margarita, California Manufacturing Center of Excellence. We are ready to serve additional business in California now as we work to broaden our manufacturing reach globally through strategic partnerships."
Liquidmetal Technologies and ENGEL Host Advanced Manufacturing Symposium in Stuttgart
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--January 19, 2016--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, announced today that it would be co-hosting an advanced manufacturing symposium in Stuttgart, Germany, on January 19-20, to inform product developers, production managers and managing directors in the metal and plastics processing industries about the advanced capabilities currently available and in use by Liquidmetal Technologies at its Manufacturing Center of Excellence.
"We are excited to team with ENGEL and Materion to introduce a new metals manufacturing process technology, injection molding machines, and alloys that offer customers an exciting alternative to traditional processes," said Paul Hauck, Vice President of World-Wide Sales & Marketing. "We will be participating with ENGEL and Materion to educate a collection of world-class European and global companies on the opportunities for innovative design solutions available with the Liquidmetal process."
Highlights of the 2-day Symposium:
-- Live demo of the ENGEL Liquidmetal machine with on-site production of
precision, complex parts that have incredible surface finish
-- Multiple presentations from Liquidmetal, Materion, and ENGEL explaining
the technical details behind this emerging manufacturing capability
-- Industry specific applications for Medical, Automotive, Aerospace and
more
-- Panel of experts to answer specific questions from attendees
-- Early-registration limited to 200 of the highest potential
representatives over two days
Liquidmetal Technologies Receives 2016 Production Contract
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--January 19, 2016--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, received an annual purchase order to produce a critical medical device component for CoNextions, a medical device developer and manufacturer. The significant order was received on heels of Liquidmetal having recently completed production tooling and the delivery of initial parts on a very aggressive timeline.
"We are thrilled to have been selected by CoNextions as a key supplier and to have the opportunity to demonstrate the capabilities of our technology and outstanding engineering and manufacturing team," said Paul Hauck, Vice President of World-Wide Sales and Marketing. "Liquidmetal was asked to complete production tooling and initial parts against a challenging schedule. Our ability to meet their demanding timeline is a reflection of what can happen through close collaboration between two companies and having highly talented and committed professionals in both organizations."
Liquidmetal Technologies Receives ISO 9001:2008 Certification
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--January 06, 2016--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, received its formal ISO 9001:2008 certification, adding an important quality accreditation to the company.
"Our business has a strong commitment to ongoing quality and customer satisfaction. Receiving our ISO certification exemplifies that," said Paul Hauck, Vice President of World-Wide Sales and Marketing. "Our ISO certification will help build customer confidence in our attention to quality."
"The Liquidmetal organization did an admirable job implementing the ISO 9001 standard and passing its certification audit in an impressive 9 months," said Tom Steipp, CEO and President of Liquidmetal Technologies. "Achieving this result was no small undertaking. Every individual in the company played a critical role and it's a testament to the organization's focus on quality."
Liquidmetal Technologies Announces Pre-Production Shipment for Medical Device Component from CoNextions Medical
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--December 17, 2015--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, announced today it is shipping a pre-production order to CoNextions Medical for a key component to be used for suture based tendon repairs. The initial parts delivery will be used to complete various testing and will be followed by a full production shipment currently scheduled for early next year. This delivery represents the ongoing manufacturing solutions for CoNextions design efforts that are taking advantage of the Liquidmetal materials and molding technology.
Liquidmetal Technologies to Directly Sell Custom, Hybrid Knives
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--December 08, 2015--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, will be selling hybrid knives for a limited time on its website www.liquidmetal.com. The Liquidmetal Hybrid Knife is an innovative product that exemplifies simple elegance through its design, precision, and appearance. Manufactured using the Liquidmetal process, the hybrid knife embodies a geometry that is impractical to produce with any other metal forming process. The knife is also processed with a special anodized black finish.
"The ability of the Liquidmetal process technology to provide such a high level of part to part dimensional precision and repeatability is showcased by the precise fit of the knife blade and protector," said Paul Hauck, Vice President of World-Wide Sales and Marketing. "After more than 30 years of involvement with metal parts fabrication technologies, I have not witnessed anything like the precision of this molding technology. It's really exciting to see the results first hand in an attractive and interesting product that would make a great addition to any knife collection."
Liquidmetal Technologies to Present at LD MICRO Conference
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--November 24, 2015--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, will be presenting at next week's LD MICRO Investment Newsletter Conference in Los Angeles. Liquidmetal Technologies CEO Tom Steipp, CFO Tony Chung, and VP Sales Paul Hauck will give their presentation on December 2nd at The Luxe Sunset Hotel at 10:00 a.m.
Some 200 companies will give their presentations to an anticipated audience of fund managers, analysts, and traders from over 185 firms.
Liquidmetal Technologies Announces Production Order for an Innovative Medical Device Component from CoNextions Medical
RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--October 19, 2015--
Liquidmetal(R) Technologies, Inc. (OTCQB: LQMT), the world's leading developer of amorphous alloys, announced today that it has received a production order for an innovative medical device component.
"Our emerging partnership with medical products developer, CoNextions Medical, is demonstrating the advanced capabilities of both businesses and paving the way for the delivery of an innovative medical device." said Tom Steipp, CEO of Liquidmetal Technologies. "Our collaborative engineering design efforts have yielded a manufacturing solution for a key medical device component based on the principle values of the Liquidmetal materials and molding technology."
"CoNextions Medical current focus is on providing a superior alternative to suture-based tendon repairs. The ability to mold complex metal shapes with highly impressive material properties in a single process step, has provided an important manufacturing solution for our medical device," said Richard J. Linder, President and CEO of CoNextions Medical. "I am excited about the progress our two organizations have made together and we look forward to working with Liquidmetal Technologies."
the only way it reaches those prices is if investors are given a reason to keep buying the stock and buying it at higher prices. I think everyone can agree that is certainly no given.
i would love to see .15 or .25 reached but how you can possibly say "LQMT knows it will hit those prices." That's impossible to predict unless you have a crystal ball.
over 600K traded last 6 minutes so very well could be so momentum buyers in the morning
very nice way to close
couple of nice buys just now at the ask....would be nice to get over 10 million shares traded and hold 25% gains
your lips to God's ears
A patent in no way means that it has been commercialized in an actual product. To infer so is quite obnoxious. Can you please provide some proof, other than conjecture, that APPLE has been using a formulation of our LQMT or LQMT process in these parts?
Thank you!!
there have been hundreds of patents released showing plans to use LQMT in their products and none have come to fruition, yet. Why would this be any different?
No need for posters to try and explain the company is running out of money. It is all in black and white, directly from the company itself.
"We have limited funds to support our current operations.
We have a relatively limited history of producing bulk amorphous alloy components and products on a mass-production scale. Furthermore, the ability of future contract manufacturers to produce our products in desired quantities and at commercially reasonable prices is uncertain and is dependent on a variety of factors that are outside of our control, including the nature and design of the component, the customer’s specifications, and required delivery timelines. Such factors will likely require that we raise additional funds to support our operations beyond 2016 and into 2017. There is no assurance that we will be able to raise such additional funds on acceptable terms, if at all. If we raise additional funds by issuing securities, existing stockholders may be diluted. If funding is insufficient at any time in the future, we may be required to alter or reduce the scope of our operations or to cease operations entirely.
Funding from our 2014 Purchase Agreement may be limited or insufficient to fund our operations or to implement our strategy.
The extent to which we utilize the 2014 Purchase Agreement (see note 3 in the accompanying footnotes to the consolidated financial statements) as a source of funding will depend on a number of factors, including the prevailing market price of our common stock, the volume of trading in our common stock and the extent to which we are able to secure funds from other sources. The number of shares that we may sell under the 2014 Purchase Agreement on any given day and during the term of the agreement is limited. Additionally, we may not effect any sales of shares of our common stock under the 2014 Purchase Agreement during the continuance of an event of default or on any trading day that the closing sale price of our common stock is less than $0.10 per share. Even if we are able to access the full $30.0 million under the 2014 Purchase Agreement, we may still need additional capital to fully implement our business, operating and development plans.
If we elect to raise additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives, as well as through sales of common stock under the 2014 Purchase Agreement. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing acquisition, licensing, development and commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.
If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected and we may be unable to continue our operations.
We have incurred significant operating losses in the past and may not be able to achieve or sustain profitability in the future.
We have experienced significant cumulative operating losses since our inception. Our operating loss for the fiscal years ended December 31, 2015, 2014, and 2013 were $9.3 million, $8.9 million, and $6.1 million, respectively. We had an accumulated deficit of approximately $218.0 million at December 31, 2015, approximately $210.6 million at December 31, 2014, and approximately $204.1 million at December 31, 2013. We anticipate that we may continue to incur operating losses for the foreseeable future. Consequently, it is possible that we may never achieve positive earnings and, if we do achieve positive earnings, we may not be able to achieve them on a sustainable basis."
that excuse is bullsheet. they already issued a press release that Conextion is using the material in the new breakthrough medical device. why would apple give two sheets about what part of the medical device is using Liquidmetal. This is a very tired argument.
once again a realistic view, granted it is an opinion, of the latest bit of "information" for us investors to have to translate/speculate since we never get concrete information from this company. Could that sentence mean there are 18,000 Engel machines being ramped up for production in Europe? Sure it can. Everyone can choose where to place their bets on that one.
The CoNextions device? Why the hell do we have to sit here and guess, is it the anvil, is it the staple, etc etc etc. Just freaking tell us!